Stock ATOS ATOSSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
1.53 USD +0.66% Intraday chart for Atossa Therapeutics, Inc. +11.68% +73.86%
04-15 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer CI
04-09 Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14.34 37.11 202.6 66.92 110.3 191.7 - -
Enterprise Value (EV) 1 14.34 37.11 202.6 66.92 110.3 191.7 191.7 191.7
P/E ratio -0.77 x -0.48 x -8.89 x -2.52 x -3.67 x -5.72 x -5.16 x 6.65 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - - 2.05 x
EV / Revenue - - - - - - - 2.05 x
EV / EBITDA - - - - - - - -
EV / FCF - - - - -5.26 x -7.99 x -5.33 x -27.4 x
FCF Yield - - - - -19% -12.5% -18.8% -3.65%
Price to Book - 1.66 x 1.47 x 0.57 x 1.22 x 3.06 x - -
Nbr of stocks (in thousands) 9,131 39,068 126,624 126,624 125,304 125,304 - -
Reference price 2 1.570 0.9500 1.600 0.5285 0.8800 1.530 1.530 1.530
Announcement Date 20-03-26 21-03-31 22-02-28 23-03-22 24-04-01 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 93.69
EBITDA - - - - - - - -
EBIT 1 -17.27 -14.61 -20.52 -27.69 -31.38 -36.58 -42.33 21.06
Operating Margin - - - - - - - 22.47%
Earnings before Tax (EBT) 1 -17.24 -17.83 -20.61 -26.96 -30.09 -35.34 -41.73 21.59
Net income 1 -17.24 -17.83 -20.61 -26.96 -30.09 -35.34 -41.73 17.86
Net margin - - - - - - - 19.06%
EPS 2 -2.030 -1.970 -0.1800 -0.2100 -0.2400 -0.2675 -0.2967 0.2300
Free Cash Flow 1 - - - - -20.96 -24 -36 -7
FCF margin - - - - - - - -7.47%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-03-26 21-03-31 22-02-28 23-03-22 24-04-01 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -5.159 -4.828 -4.747 -6.595 -8.205 -8.138 -7.098 -7.793 -7.468 -9.019 -8.5 -8.8 -9.1 -9.467
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -5.197 -4.832 -4.786 -6.672 -8.011 -7.491 -6.281 -9.83 -6.229 -7.754 -8.133 -8.467 -8.8 -9.233
Net income 1 -5.197 -4.832 -4.786 -6.672 -8.011 -7.491 -6.281 -9.83 -6.229 -7.754 -8.133 -8.467 -8.8 -9.233
Net margin - - - - - - - - - - - - - -
EPS 2 -0.0400 -0.0400 -0.0400 -0.0500 -0.0600 -0.0600 -0.0500 -0.0800 -0.0500 -0.0600 -0.0633 -0.0633 -0.0667 -0.0700
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 21-11-15 22-02-28 22-05-09 22-08-08 22-11-07 23-03-22 23-05-15 23-08-14 23-11-13 24-04-01 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - -21 -24 -36 -7
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 0.5700 1.090 0.9300 0.7200 0.5000 - -
Cash Flow per Share - - - - - - - -
Capex 1 - 0.01 0.01 - 0.01 0.5 0.5 0.9
Capex / Sales - - - - - - - 0.96%
Announcement Date 20-03-26 21-03-31 22-02-28 23-03-22 24-04-01 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.53 USD
Average target price
4.583 USD
Spread / Average Target
+199.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ATOSSA THERAPEUTICS, INC. Stock Atossa Therapeutics, Inc.
+73.86% 192M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.37% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. Financials Atossa Therapeutics, Inc.